PLSENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PULSE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$47.55+3.12 (+7.02%)
Close on Oct 19, 2026
- Market cap
- $3.29B
- P/E (TTM)
- –
- Dividend yield
- –
Pulse Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Market Cap | $3.39B | $230.55M |
| Enterprise Value | $3.29B | $202.97M |
| PS Ratio | 2861.93 | 3.11 |
| PB Ratio | 34.08 | 3.14 |
| P/TBV Ratio | 35.15 | 4.57 |
Enterprise value
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| EV / Sales | 2776.18 | 2.92 |
Income (trailing twelve months)
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Revenue | $1.19M | $102.39M |
| Gross Profit | $3.00K | $60.36M |
| Operating Income | -$83.04M | -$4.31M |
| Net Income | -$80.06M | -$6.57M |
| EBITDA | -$83.04M | -$1.98M |
| EPS (Diluted) | -$1.18 | -$0.07 |
Margins
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Gross Margin | 0.25% | 55.1% |
| Operating Margin | -7007.8% | -6.04% |
| Profit Margin | -6755.8% | -10.5% |
| EBITDA Margin | -7007.8% | -2.67% |
| FCF Margin | -5180.4% | -0.30% |
Returns
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -78.5% | -19.2% |
| Return on Assets (ROA) | -67.9% | -13.3% |
| Return on Capital Employed (ROCE) | -79.4% | -9.07% |
Growth
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -20.6% | 7.08% |
Balance sheet
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $101.62M | $37.33M |
| Net Cash (Debt) | $101.62M | $3.92M |
| Net Cash Per Share | $1.42 | $0.28 |
| Equity (Book Value) | $99.50M | $57.36M |
| Book Value Per Share | $1.40 | $2.81 |
| Tangible Book Value | $96.49M | $10.71M |
| Working Capital | $94.72M | $54.64M |
Financial position
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Current Ratio | 9.63 | 2.50 |
| Quick Ratio | 9.27 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$61.10M | -$653.46K |
| Capital Expenditures | -$290.00K | -$3.69M |
| Free Cash Flow | -$61.39M | -$835.02K |
| FCF Per Share | -$0.86 | -$0.02 |
Efficiency
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.59 |
| Inventory Turnover | 8.24 | 2.21 |
| Revenue Per Employee | $10.22K | $322.57K |
| Profits Per Employee | -$690.14K | -$51.88K |
| Employee Count | 116 | 185 |
Dividends and yields
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -2.36% | -6.91% |
| FCF Yield | -1.81% | -0.56% |
Shares
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 71,322,600 | 44,856,700 |
| Shares Change (YoY) | 5.75% | 3.35% |
| Shares Change (QoQ) | 3.77% | 0.27% |
| Float | 20,537,500 | 37,097,900 |
| Shares Held by Insiders | 71.2% | 10.6% |
| Shares Held by Institutions | 15.0% | 63.5% |
Scores
| Measure | Pulse Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 119.16 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Pulse Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.